Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/02/20 | $7,000,000 | Seed |
Biobrit BioRock Ventures CAM Capital Charlie McDermott | undisclosed |
